She Found ECCT when Exploring Effective Alternative Treatment for Stage 3C Colon Cancer

A Malaysian, female in her 50s began experiencing unusual symptoms in late 2023. Persistent diarrhea—sometimes more than 10 times a day—became a significant concern. After a series of medical tests, she was diagnosed with Stage 3C colon cancer, which had already spread to nearby lymph nodes. The tumor was larger than 6cm in size and located near the rectum, causing significant disruption.

To combat the cancer, she started treatment with radiotherapy and oral chemotherapy in late August 2023. Over the course of more than 20 radiotherapy sessions, she experienced some side effects, including mild constipation, but her determination kept her going. In December 2023, she underwent surgery to remove the tumor, and doctors were hopeful that the treatment would effectively remove all the cancer. However, the pathology report from her surgery revealed near to half of the lymph nodes still had cancerous cells, signaling that more treatment would be necessary.

Just before her surgery, she learned about ECCT, a non-invasive treatment designed to support the body in fighting cancer. ECCT uses low-frequency electric fields to disrupt the growth of cancer cells. After careful consideration and consultation with her doctors, she began ECCT treatment trusting its an Effective Alternative Treatment for Stage 3C Colon Cancer in December 2023.

She chose ECCT for several reasons:

1. To complement conventional treatments: Despite the success of surgery, the lingering cancer in her lymph nodes required additional support.

2. Non-invasive and drug-free: ECCT offers a safe and gentle option without adding further stress on her body.

3. Hope for a better outcome: After a tough journey, she wanted to do everything possible to prevent recurrence.

Monitoring and Encouraging Results

As the months passed, her health gradually improved, and her scans revealed positive progress:

• Follow-up PET scan in February 2024 showed no signs of cancer recurrence.

• CT scan in October 2024 revealed no distant metastatic disease and only left with three tiny residual mesorectal nodes

• MRI brain and chest scans in December 2024 confirmed no abnormal growths or lesions

• Ultrasound in October 2024 showed no concerning signs of cancer or metastasis, and only small, residual nodes in the mesorectal region.

These results confirmed that her body was responding well to the therapies she was doing, and there was no indication of cancer spreading further.

Looking Ahead: A Brighter Future with ECCT

Her journey continues, but with hope and confidence. By incorporating ECCT into her treatment regimen, she has taken proactive steps toward ensuring that her body remains strong and resilient. She continues with regular ECCT treatments and will continue to undergo further monitoring through periodic scans and tests to ensure further clearance, no metastasis and recurrence.

Her experience is a testament to the potential of combining traditional cancer treatments with innovative therapies like ECCT for better outcomes. Through this comprehensive approach, she has managed to stay active, and she remains optimistic about her future.